Pablo Cagnoni Over of the course of my career, I have been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases. I have played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor, Blincyto, Exjade, Folotyn, Glivec, Jakavi, Kyprolis, Signifor, Tarceva, Tasigna and Zykadia. I’m currently Chief Executive Officer of Rubius Therapeutics, where I am focused on advancing the company’s vision of creating life-changing cellular medicines. Most recently, I served as President and CEO of Tizona Therapeutics, a privately held biotech company developing next generation immunotherapies for the treatment of cancer. I joined Tizona as the company’s first employee and grew the organization to support the filing of its first IND. Prior to Tizona, I served as President of Onyx Pharmaceuticals, where I had global strategic oversight and accountability of the Onyx portfolio from early product development to commercialization. At the time of my departure, Onyx was on track to deliver yearly revenues in excess of $1B and had more than 800 employees. Previously, I was SVP and Global
President Incyte and Global Head of R&D
President and Head of R&D
Chief Executive Officer
Executive Partner
President and Chief Executive Officer
President & Chief Executive Officer
President
EVP and Global Head R&D and Technical Operations,
fellowship in Hematology and Oncology
fellowship in Stem Cell Transplantation